Stock CRMD CORMEDIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CorMedix Inc.

Equities

CRMD

US21900C3088

Real-time Estimate Cboe BZX
Other stock markets
 01:25:54 2024-05-23 pm EDT 		5-day change 1st Jan Change
5.125 USD -1.63% Intraday chart for CorMedix Inc. -2.50% +34.84%
May. 09 Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on CorMedix Inc.

Price target over the last 5 years

History of analyst recommendation changes

4df2f.RB7Znwem0YqGhLDMdEiOZTc97FX0Seb5pXGNNmevaOM.Nli6-mXBgNLV6tL-Iz3kVFpEgj2iL5-OkwnlblLXXYsJKZP0ZMed_rfn_Q~66a6ef644815690f19dfc9d1d54d26d2

Analyst Recommendations on CorMedix Inc.

RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier MT
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk MT
RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved' MT
JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating MT
JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating MT
Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating MT
JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperform Rating MT
Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating MT
CORMEDIX : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating MT
CORMEDIX : B. Riley Lowers CorMedix' Price Target to $13.50 from $25 After FDA Rejects DefenCath Due to Manufacturing Issues, Keeps Buy Rating MT
CORMEDIX : Needham Starts CorMedix at Buy With $31 Price Target MT
CORMEDIX : B. Riley Adjusts CorMedix' Price Target to $25 From $11, Keeps Buy Rating MT
CORMEDIX : Truist Securities Adjusts CorMedix PT to $35 From $20, Maintains Buy Rating MT
CORMEDIX : Truist Securities Adjusts CorMedix' Price Target to $35 from $20, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.21 USD
Average target price
13 USD
Spread / Average Target
+149.52%
High Price Target
19 USD
Spread / Highest target
+264.68%
Low Price Target
9 USD
Spread / Lowest Target
+72.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CorMedix Inc.

RBC Capital Markets
JMP Securities
Truist Securities
Needham & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRMD Stock
  4. Consensus CorMedix Inc.